Pay in 4 interest-free payments of $5.56 Learn more
Ships within 48 hours · Estimated delivery Aug 28 - Sep 2
We check in weekly or bi-weekly to monitor your results and help manage any side effects
VK2735 Research# VK2735's evidence base consists of phase 2 trials: VENTURE (subcutaneous): 176 adults with obesity, 13 weeks, up to 14.7% weight loss from baseline (placebo-adjusted 13.1%) VENTURE-Oral: Oral tablet formulation, 13 weeks, up to 12.2% weight loss vs 1.3% placebo Phase 3 VANQUISH program: Planned but not yet initiated at time of writing Evidence level: Low -- promising phase 2 data only, short duration, small sample sizes, no head-to-head comparisons
Kahn, Metabolites as regulators of insulin sensitivity and metabolism
Purpose-built for physicians Q&A: Liraglutide outperforms colesevelam in reducing stool frequency in bile acid diarrhea Liraglutide reduced stool frequency in a small subset of patients with bile acid diarrhea and warrants consideration as a potential new treatment modality, according to research in The Lancet Gastroenterology and Hepatology
That difference may require a patient to measure medication with a syringe
